Isn't it possible or even likely that the 'current standard of care' has improved in terms of efficacy (since last trials) thus leading to substantially better results for the placebo. If this is so it might explain the lack of interest in partnering by manufacturers of pressure bandages and whatever else makes up the current standard of care. In addition - it may be that the medical services associated with administering 'current standard of care' for these trials are superior to those used in original trials.
For what it's worth - I'm out of biotech's - will keep a holding in OPT though, but techs amd holes in the ground, here I come....
- Forums
- ASX - By Stock
- DLM
- Ann: Results of Phase 2 Clinical Trial
Ann: Results of Phase 2 Clinical Trial, page-117
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable